Vitamin D and neurology

Internal medicine

Pediatrics

Adverse effect

PHEX

Short stature

Hypophosphatemia

Urinary system

Gastroenterology

Endocrinology

Fibroblast growth factor 23

Rickets

Hypercalciuria

Creatinine

Calcium

Parathyroid hormone

Hypophosphatemic Rickets

Medicine

The Lancet Diabetes & Endocrinology

Burosumab had a favourable safety profile, increased serum phosphorus, and improved rickets and prevented early declines in growth in children aged 1–4 years with X-linked hypophosphataemia. These findings could substantially alter the treatment of young children with X-linked hypophosphataemia.

Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial